|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-8-2
|
|
pubmed:abstractText |
The rationale for intraperitoneal (IP) chemotherapy is to expose peritoneal tumors to high drug concentrations. While multiple phase III trials have established the significant survival advantage by adding IP therapy to intravenous therapy in optimally debulked ovarian cancer patients, the use of IP chemotherapy is limited by the complications associated with indwelling catheters and by the local chemotherapy-related toxicity. The present study evaluated the effects of drug carrier on the disposition and efficacy of IP paclitaxel, for identifying strategies for further development of IP treatment.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-10343192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-10453726,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-10637064,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-10697528,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-11146078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-11181662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-11887848,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-11948138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-12538489,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-1355523,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-15142340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-15570001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-15948030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-16102265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-16172456,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-16204007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-16368440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-16394300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-2019667,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-2298407,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-3155917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-3815369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-4067845,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-7035796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-7471076,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-7735481,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-7799018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-7912528,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-8110061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-8290652,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-8912534,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-8960474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17447121-9322877
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0724-8741
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1691-701
|
|
pubmed:dateRevised |
2010-9-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17447121-Absorption,
pubmed-meshheading:17447121-Animals,
pubmed-meshheading:17447121-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17447121-Drug Carriers,
pubmed-meshheading:17447121-Female,
pubmed-meshheading:17447121-Injections, Intraperitoneal,
pubmed-meshheading:17447121-Injections, Intravenous,
pubmed-meshheading:17447121-Mice,
pubmed-meshheading:17447121-Mice, Inbred BALB C,
pubmed-meshheading:17447121-Nanoparticles,
pubmed-meshheading:17447121-Paclitaxel,
pubmed-meshheading:17447121-Particle Size
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.
|
|
pubmed:affiliation |
College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
